市場調査レポート
商品コード
1226802

南米のECMO市場の2028年までの予測- 地域別分析- モダリティ、アプリケーション、年齢層別

South America ECMO Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Modality (Venoarterial ECMO, Venovenous ECMO, and Arteriovenous ECMO), Application (Respiratory and Cardiology), and Age Group (Adults, Pediatrics, and Neonates)

出版日: | 発行: The Insight Partners | ページ情報: 英文 112 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
南米のECMO市場の2028年までの予測- 地域別分析- モダリティ、アプリケーション、年齢層別
出版日: 2023年01月25日
発行: The Insight Partners
ページ情報: 英文 112 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

南米のECMO市場は、2022年の5,300万米ドルから2028年には6,058万米ドルに成長すると予測されています。2022年から2028年までのCAGRは2.3%を記録すると推定されます。

肺移植手術におけるECMOの採用拡大が南米のECMO市場成長を後押し

肺移植は、COPD、特発性肺線維症(IPF)、嚢胞性線維症などの末期肺疾患を患う患者にとって、生活の質を向上させるための救命治療の選択肢です。ECMOは、術前、術中、術後など、肺移植のすべてのフェーズで使用される汎用性の高いツールです。ECMOは、肺移植を受ける患者さんの橋渡し役として機能します。したがって、生命を脅かす肺疾患の患者を管理するために、肺移植中のECMOの採用は急速に拡大しています。一次移植片機能不全(PGD)は、肺移植後の死亡の主な原因です。したがって、ECMOは、肺移植後のPGDの治療に優先的に使用されます。このように、ECMO装置の需要は、PGDに苦しむ患者を治療するために高まっているのです。

南米のECMO市場の概要

南米のECMO市場は、ブラジル、アルゼンチン、その他南米に区分されます。2022年はブラジルが市場を独占しています。World Heart Federationによると、ブラジルでは心血管疾患などの非伝染性疾患が総死亡数の74%を占めています。Global Burden Study(GBD)およびBrazilian Unified Health Systemによると、2019年のブラジルの死因のトップは心血管疾患でした。ブラジルでは高齢化が進んでいるため、心血管疾患の有病率は年々増加傾向にあります。GBDによると、虚血性心疾患(IHD)の患者数は2019年に400万人に達しました。さらに、IHDによる死亡が約171,246件報告されており、2019年のブラジルにおける心血管疾患による死亡の43%、総死亡の12%を占めています。このように、ブラジルにおける心血管疾患患者の増加が、同国におけるECMO市場の成長を牽引しています。

南米のECMO市場の収益と2028年までの予測(金額)

南米のECMO市場のセグメント化

南米のECMO市場は、モダリティ、アプリケーション、年齢層、国に基づいてセグメント化されています。

モダリティに基づき、南米のECMO市場は静脈動脈性ECMO、静脈性ECMO、動静脈性ECMOに区分されます。2022年には、静脈動脈ECMOセグメントが最大の市場シェアを占めています。

アプリケーションに基づき、南米のECMO市場は呼吸器と心臓病学に二分されます。2022年には呼吸器分野がより大きな市場シェアを占めました。

年齢層に基づき、南米のECMO市場は、成人、小児科、新生児に区分されます。2022年には成人セグメントが最も大きな市場シェアを占めました。

国別に見ると、南米のECMO市場は、ブラジル、アルゼンチン、その他南米に分類されています。地域別分析では、2022年にブラジルが市場を独占したとされています。

ABIOMED Inc、Braile Biomedica、Fresenius Medical Care AG &Co KGaA、Getinge AB、LivaNova Plc、Medtronic Plc、MicroPort Scientific Corporation、Nipro Medical Corporation、Terumo Groupは南米のECMO市場で活動している主要企業です。

目次

第1章 イントロダクション

第2章 重要なポイント

第3章 調査手法

  • カバレッジ
  • 2次調査
  • 1次調査

第4章 南米のECMO市場- 市場環境

  • 南米のPEST分析
  • 専門家の見解

第5章 南米のECMO市場-主要な市場力学

  • 市場促進要因
    • 心血管疾患と呼吸不全の有病率の上昇
    • 肺移植術におけるECMOの採用拡大
  • 市場抑制要因
    • ECMOに関連する合併症
  • 市場機会
    • ECMO別生存率の向上
  • 今後の動向
    • 製品開発および承認の急増
  • インパクト分析

第6章 ECMO市場-南米分析

  • 南米のECMO市場収益と予測・分析

第7章 南米のECMO市場の分析:モダリティ別

  • 南米のECMO市場:モダリティ別シェア 2021年・2028年(%)
  • 静脈ECMO
  • 動静脈ECMO
  • 動静脈ECMO

第8章 南米のECMOの市場分析:アプリケーション別

  • 南米のECMO市場:アプリケーション別2021年・2028年(%)
  • 呼吸器
  • 心臓病学

第9章 南米のECMOの市場分析:年齢層別

  • 南米のECMO市場:年齢層別:2021年・2028年(%)(%)
  • 成人
  • 小児
  • 新生児

第10章 南米のECMO市場:国別分析

    • 南米
      • ブラジル
      • アルゼンチン
      • その他南米諸国

第11章 業界情勢

  • 無機的成長戦略
  • 有機的成長戦略

第12章 企業プロファイル

  • Terumo Group
  • Medtronic Plc
  • MicroPort Scientific Corporation
  • LivaNova Plc
  • Nipro Medical Corporation
  • Getinge AB
  • Braile Biomedica
  • Fresenius Medical Care AG & Co KGaA
  • ABIOMED Inc

第13章 付録

図表

List Of Tables

  • Table 1. SAM ECMO Market - Revenue and Forecast to 2028 (US$ Million)
  • Table 2. Brazil ECMO Market, by Modality - Revenue and Forecast to 2028 (USD Million)
  • Table 3. Brazil ECMO Market, by Application - Revenue and Forecast to 2028 (USD Million)
  • Table 4. Brazil ECMO Market, by Age Group - Revenue and Forecast to 2028 (USD Million)
  • Table 5. Argentina ECMO Market, by Modality - Revenue and Forecast to 2028 (USD Million)
  • Table 6. Argentina ECMO Market, by Application - Revenue and Forecast to 2028 (USD Million)
  • Table 7. Argentina ECMO Market, by Age Group - Revenue and Forecast to 2028 (USD Million)
  • Table 8. Rest of SAM ECMO Market, by Modality - Revenue and Forecast to 2028 (USD Million)
  • Table 9. Rest of SAM ECMO Market, by Application - Revenue and Forecast to 2028 (USD Million)
  • Table 10. Rest of SAM ECMO Market, by Age Group - Revenue and Forecast to 2028 (USD Million)
  • Table 11. Recent Inorganic Growth Strategies
  • Table 12. Recent Organic Growth Strategies
  • Table 13. Glossary of Terms

List Of Figures

  • Figure 1. SAM ECMO Market Segmentation
  • Figure 2. SAM ECMO Market, By Country
  • Figure 3. SAM ECMO Market Overview
  • Figure 4. SAM ECMO Market, By Modality
  • Figure 5. SAM ECMO Market, By Country
  • Figure 7. SAM: PEST Analysis
  • Figure 8. Experts Opinion
  • Figure 9. Impact Analysis: SAM ECMO Market
  • Figure 10. SAM ECMO Market - Revenue Forecast and Analysis
  • Figure 11. SAM ECMO Market Share by Modality 2021 & 2028 (%)
  • Figure 12. Venoarterial ECMO: SAM ECMO Market Revenue and Forecast To 2028 (US$ Million)
  • Figure 13. Venovenous ECMO: SAM ECMO Market Revenue and Forecast To 2028 (US$ Million)
  • Figure 14. Arteriovenous ECMO: SAM ECMO Market Revenue and Forecast To 2028 (US$ Million)
  • Figure 15. SAM ECMO Market, by Application 2021 & 2028 (%)
  • Figure 16. Respiratory : SAM ECMO Market Revenue and Forecasts To 2028 (US$ MN)
  • Figure 17. Cardiology : SAM ECMO Market Revenue and Forecasts to 2028 (US$ Mn)
  • Figure 18. SAM ECMO Market, by Age Group 2021 & 2028 (%)
  • Figure 19. Adults : SAM ECMO Market Revenue and Forecasts to 2028 (US$ Mn)
  • Figure 20. Pediatrics : SAM ECMO Market Revenue and Forecasts to 2028 (US$ Mn)
  • Figure 21. Neonates : SAM ECMO Market Revenue and Forecasts to 2028 (US$ Mn)
  • Figure 22. SAM: ECMO Market, by Key Country - Revenue (2021) (US$ Million)
  • Figure 23. SAM: ECMO, by Country, 2021 & 2028 (%)
  • Figure 24. Brazil: ECMO - Revenue and Forecast to 2028 (US$ Million)
  • Figure 25. Argentina: ECMO - Revenue and Forecast to 2028 (US$ Million)
  • Figure 26. Rest of SAM: ECMO - Revenue and Forecast to 2028 (US$ Million)
目次
Product Code: BMIRE00027974

The South America ECMO market is expected to grow from US$ 53.00 million in 2022 to US$ 60.58 million by 2028. It is estimated to record a CAGR of 2.3% from 2022 to 2028.

Growing Adoption of ECMO in Lung Transplantation Procedures Bolsters South America ECMO Market Growth

Lung transplantation is a life-saving treatment option for patients suffering from end-stage lung diseases, such as COPD, Idiopathic pulmonary fibrosis (IPF), and cystic fibrosis, to improve the quality of life. ECMO is a versatile tool used in all lung transplantation phases, such as preoperative, intraoperative, and postoperative periods. It acts as a bridge in patient undergoing lung transplantation. Therefore, the adoption of ECMO during lung transplantation is growing rapidly to manage patients with life-threatening lung disease. Primary graft dysfunction (PGD) is the leading cause of death after a lung transplant. Thus, ECMO is used penultimately in treating PGD post lung transplantation. Thus, the demand for ECMO equipment is growing for treating the patients suffering from PGD.

South America ECMO Market Overview

The SAM ECMO market is segmented into Brazil, Argentina, and the Rest of SAM. Brazil dominated the market in 2022. According to World Heart Federation, noncommunicable diseases such as cardiovascular disease accounts for 74% of total deaths in Brazil. According to Global Burden Study (GBD) and Brazilian Unified Health System, cardiovascular disease was the leading cause of death in Brazil in 2019. Due to the increasing aging population in Brazil, the prevalence of cardiovascular diseases is increasing each year. According to GBD, the number of ischemic heart disease (IHD) cases reached 4 million in 2019. Further, about 171,246 deaths were reported due to IHD, which accounted for 43% of cardiovascular deaths and 12% of total deaths in Brazil in 2019. Thus, growing cardiovascular disease cases in Brazil are driving the ECMO market growth in the country.

South America ECMO Market Revenue and Forecast to 2028 (US$ Million)

South America ECMO Market Segmentation

The South America ECMO market is segmented based on modality, application, age group, and country.

Based on modality, the SAM ECMO market is segmented into venoarterial ECMO, venovenous ECMO, and arteriovenous ECMO. The venoarterial ECMO segment held the largest market share in 2022.

Based on application, the SAM ECMO market is bifurcated into respiratory and cardiology. The respiratory segment held a larger market share in 2022.

Based on age group, the SAM ECMO market is segmented into adults, pediatrics, and neonates. The adults segment held the largest market share in 2022.

Based on country, the SAM ECMO market has been categorized into Brazil, Argentina, and the Rest of SAM. Our regional analysis states that Brazil dominated the market in 2022.

ABIOMED Inc, Braile Biomedica, Fresenius Medical Care AG & Co KGaA, Getinge AB, LivaNova Plc, Medtronic Plc, MicroPort Scientific Corporation, Nipro Medical Corporation, and Terumo Group are the leading companies operating in the SAM ECMO market.

Reasons to Buy:

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the SAM ECMO market.
  • Highlights key business priorities in order to assist companies to realign their business strategies
  • The key findings and recommendations highlight crucial progressive industry trends in the SAM ECMO market, thereby allowing players across the value chain to develop effective long-term strategies
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
  • Scrutinize in-depth SAM market trends and outlook coupled with the factors driving the ECMO market, as well as those hindering it
  • Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 The Insight Partners Research Report Guidance
  • 1.3 Market Segmentation
    • 1.3.1 SAM ECMO Market - By Modality
    • 1.3.2 SAM ECMO Market - By Application
    • 1.3.3 SAM ECMO Market - By Age Group
    • 1.3.4 SAM ECMO Market - By Country

2. Key Takeaways

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. SAM ECMO Market - Market Landscape

  • 4.1 Overview
  • 4.2 SAM PEST Analysis
  • 4.3 Experts Opinion

5. SAM ECMO Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Rising Prevalence of Cardiovascular Diseases and Respiratory Failures
    • 5.1.2 Growing Adoption of ECMO in Lung Transplantation Procedures
  • 5.2 Market Restraints
    • 5.2.1 Complications Associated with ECMO
  • 5.3 Market Opportunities
    • 5.3.1 Increasing Survival Rates with ECMO
  • 5.4 Future Trends
    • 5.4.1 Surging Product Developments and Approvals
  • 5.5 Impact Analysis

6. ECMO Market - SAM Analysis

  • 6.1 SAM ECMO Market Revenue Forecast & Analysis

7. SAM ECMO Market Analysis - By Modality

  • 7.1 Overview
  • 7.2 SAM ECMO Market Share by Modality 2021 & 2028 (%)
  • 7.3 Venoarterial ECMO
    • 7.3.1 Overview
    • 7.3.2 Venoarterial ECMO: ECMO Market Revenue and Forecast to 2028 (US$ Million)
  • 7.4 Venovenous ECMO
    • 7.4.1 Overview
    • 7.4.2 Venovenous ECMO: ECMO Market Revenue and Forecast to 2028 (US$ Million)
  • 7.5 Arteriovenous ECMO
    • 7.5.1 Overview
    • 7.5.2 Arteriovenous ECMO: ECMO Market Revenue and Forecast to 2028 (US$ Million)

8. SAM ECMO Market Analysis - By Application

  • 8.1 Overview
  • 8.2 SAM ECMO Market, By Application 2021 & 2028 (%)
  • 8.4 Respiratory
    • 8.4.1 Overview
    • 8.4.2 Respiratory Market Revenue and Forecast to 2028 (US$ Mn)
  • 8.5 Cardiology
    • 8.5.1 Overview
    • 8.5.2 Cardiology Market Revenue and Forecast to 2028 (US$ Mn)

9. SAM ECMO Market Analysis - By Age Group

  • 9.1 Overview
  • 9.2 SAM ECMO Market, By Age Group 2021 & 2028 (%)
  • 9.3 Adults
    • 9.3.1 Overview
    • 9.3.2 Adults Market Revenue and Forecast to 2028 (US$ Mn)
  • 9.4 Pediatrics
    • 9.4.1 Overview
    • 9.4.2 Pediatrics Market Revenue and Forecast to 2028 (US$ Mn)
  • 9.5 Neonates
    • 9.5.1 Overview
    • 9.5.2 Neonates Market Revenue and Forecast to 2028 (US$ Mn)

10. SAM ECMO Market - Country Analysis

  • 10.1 Overview
    • 10.1.1 SAM: ECMO, by Country, 2021 & 2028 (%)
      • 10.1.1.1 Brazil: ECMO - Revenue and Forecast to 2028 (US$ Million)
        • 10.1.1.1.1 Overview
        • 10.1.1.1.2 Brazil: ECMO - Revenue and Forecast to 2028 (US$ Million)
        • 10.1.1.1.3 Brazil: ECMO, by Modality, 2019-2028 (US$ Million)
        • 10.1.1.1.4 Brazil: ECMO, by Application, 2019-2028 (US$ Million)
        • 10.1.1.1.5 Brazil: ECMO, by Age Group, 2019-2028 (US$ Million)
      • 10.1.1.2 Argentina: ECMO - Revenue and Forecast to 2028 (US$ Million)
        • 10.1.1.2.1 Overview
        • 10.1.1.2.2 Argentina: ECMO - Revenue and Forecast to 2028 (US$ Million)
        • 10.1.1.2.3 Argentina: ECMO, by Modality, 2019-2028 (US$ Million)
        • 10.1.1.2.4 Argentina: ECMO, by Application, 2019-2028 (US$ Million)
        • 10.1.1.2.5 Argentina: ECMO, by Age Group, 2019-2028 (US$ Million)
      • 10.1.1.3 Rest of SAM: ECMO - Revenue and Forecast to 2028 (US$ Million)
        • 10.1.1.3.1 Overview
        • 10.1.1.3.2 Rest of SAM: ECMO - Revenue and Forecast to 2028 (US$ Million)
        • 10.1.1.3.3 Rest of SAM: ECMO, by Modality, 2019-2028 (US$ Million)
        • 10.1.1.3.4 Rest of SAM: ECMO, by Application, 2019-2028 (US$ Million)
        • 10.1.1.3.5 Rest of SAM: ECMO, by Age Group, 2019-2028 (US$ Million)

11. Industry Landscape

  • 11.1 Overview
  • 11.2 Inorganic Growth Strategies
    • 11.2.1 Overview
  • 11.3 Organic Growth Strategies
    • 11.3.1 Overview

12. Company Profiles

  • 12.1 Terumo Group
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Medtronic Plc
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 MicroPort Scientific Corporation
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 LivaNova Plc
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Nipro Medical Corporation
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Getinge AB
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 Braile Biomedica
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 Fresenius Medical Care AG & Co KGaA
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 ABIOMED Inc
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments

13. Appendix

  • 13.1 About The Insight Partners
  • 13.2 Glossary of Terms